title: Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study.
abstract: Chronic hepatitis C virus infections (HCV) cause a significant public health burden. Introduction of telaprevir (TVR) and boceprevir (BOC) has increased sustained virologic response rates (SVR) in genotype 1 patients but were accompanied by higher treatment costs and more side effects. Aim of the study was to assess outcomes and costs of treating HCV with TVR or BOC in routine care.
  Data was obtained from a non-interventional study. This analysis relates on a subset of 1,786 patients for whom resource utilisation was documented. Sociodemografic and clinical parameters as well as resource utilisation were collected using a web-based data recording system. Costs were calculated using official remuneration schemes.
  Mean age of patients was 49.2 years, 58.6% were male. In treatment-naive patients SVR-rates of 62.2% and 55.7% for TVR and BOC were observed (prior relapser: 68.5% for TVR and 63.5% for BOC; prior non-responder: 45.6% for TVR and 39.1% for BOC). Treatment costs are dominated by costs for pharmaceuticals and range between €39,081 and €53,491. We calculated average costs per SVR of €81,347 (TVR) and €70,163 (BOC) in treatment-naive patients (prior relapser: 78,089 €/SVR for TVR and 82,077 €/SVR for BOC; prior non-responder: 116,509 €/SVR for TVR and 110,156 €/SVR for BOC). Quality of life data showed a considerable decrease during treatment.
  Our study is one of few investigating both, outcomes and costs, of treating HCV in a real-life setting. Data can serve as a reference in the discussion of increasing costs in recently introduced agents.
authors.affiliation: Institute for Epidemiology, Social Medicine and Health Systems Research, Hannover Medical School, Hannover, Germany.
authors.forename: Jona T
authors.initials: JT
authors.lastname: Stahmeyer
authors.affiliation: Department of Internal Medicine, Krankenhaus Nordwest, Frankfurt a.M., Germany.
authors.forename: Siegbert
authors.initials: S
authors.lastname: Rossol
authors.affiliation: Department of Internal Medicine, Krankenhaus Nordwest, Frankfurt a.M., Germany.
authors.forename: Florian
authors.initials: F
authors.lastname: Bert
authors.affiliation: Leberpraxis, Hannover, Germany.
authors.forename: Klaus H W
authors.initials: KH
authors.lastname: Böker
authors.affiliation: Schwerpunktpraxis Bonn, Bonn, Germany.
authors.forename: Harald-Robert
authors.initials: HR
authors.lastname: Bruch
authors.affiliation: University Hospital Heidelberg, Dept. of Gastroenterology, Heidelberg, Germany.
authors.forename: Christoph
authors.initials: C
authors.lastname: Eisenbach
authors.affiliation: St. Josefs Hospital, Offenburg, Germany.
authors.forename: Ralph
authors.initials: R
authors.lastname: Link
authors.affiliation: Medical Practice, Berlin, Germany.
authors.forename: Christine
authors.initials: C
authors.lastname: John
authors.affiliation: Center for HIV and Hepatogastroenterology, Duesseldorf, Germany.
authors.forename: Stefan
authors.initials: S
authors.lastname: Mauss
authors.affiliation: Leberzentrum am Checkpoint, Berlin, Germany.
authors.forename: Renate
authors.initials: R
authors.lastname: Heyne
authors.affiliation: Dept. of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany.
authors.forename: Eckart
authors.initials: E
authors.lastname: Schott
authors.affiliation: e-factum - GmbH, Butzbach, Germany.
authors.forename: Heike
authors.initials: H
authors.lastname: Pfeiffer-Vornkahl
authors.affiliation: Center of Gastroenterology, Herne, Germany.
authors.forename: Dietrich
authors.initials: D
authors.lastname: Hüppe
authors.affiliation: Institute for Epidemiology, Social Medicine and Health Systems Research, Hannover Medical School, Hannover, Germany.
authors.forename: Christian
authors.initials: C
authors.lastname: Krauth
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D005260:Female; D017048:Health Care Costs; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011480:Protease Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D011788:Quality of Life
chemical_list: D000998:Antiviral Agents; D011480:Protease Inhibitors